Latest News

(UroToday.com) ModraDoc006 is a novel, oral tablet formulation of docetaxel. To enhance bioavailability, it is co-administered with ritonavir (r), an inhibitor of cytochrome P450 3A4 and P-glycoprotein. The oral combination, noted as ModraDoc006/r, has potential advantages in terms of patient convenience, elimination of infusion-related reactions, and avoiding prophylactic steroid administration, as well as safety benefits. At […]

(UroToday.com) In this session, Martin Gleave discusses alteration in the PI3K signaling pathway as an important molecular subtype of metastatic castration-resistant prostate cancer. Alterations in PI3K signaling contribute to the pathogenesis of many cancers. PTEN, a tumor suppressor that opposes the action of PI3K by converting PIP3 back to PIP2, is frequently lost in prostate cancer. […]

(UroToday.com) The TRITON2 study led to the approval of the PARP inhibitor rucaparib in patients with BRCA-mutated mCRPC that has progressed on prior androgen receptor signaling inhibition and one taxane chemotherapy. While response rates to rucaparib in different subgroups (germline vs. somatic, type of alteration) were similar, it is unknown how other co-occurring mutations, especially those […]

(UroToday.com) There were approximately 81,400 new cases of bladder cancer diagnosed in 2020 and nearly 90% of these cases are urothelial carcinoma. Unresectable, locally advanced, or metastatic urothelial carcinoma is present in nearly 20% of all invasive urothelial carcinoma cases worldwide. Immune checkpoint inhibitors have demonstrated long-term responses with tolerable safety profiles in patients with metastatic […]

(UroToday.com) Comprehensive genomic profiling by next-generation sequencing of circulating tumor DNA (ctDNA) from plasma provides a minimally invasive method to identify targetable genomic alterations and resistance mechanisms in patients with metastatic castration-resistant prostate cancer (mCRPC). However, the circulating tumor fraction in patients with mCRPC and the clinical validity of genomic alterations detected in plasma remains unknown. […]

(UroToday.com)Biochemical recurrence is a not infrequent occurrence following local therapy for prostate cancer, utilizing either radiotherapy or radical prostatectomy. Following biochemical relapse, patients may have disease either locally in the pelvic or more distantly. An understanding of the location and burden of recurrence disease is important in guiding subsequent therapies.

(UroToday.com) SARS-CoV-2 entry into host lung cells is facilitated by the transmembrane protease TMPRSS2, which is expressed in both lung and prostate tissue. Pre-clinical data has suggested that TMPRSS2 expression can be modulated by the androgen receptor and that androgen deprivation therapy may protect patients from SARS-CoV-2 infection and decrease the severity of COVID-19.

(UroToday.com) As the most common non-cutaneous cancer of men in the United States, prostate cancer affects the African-American population with higher incidence and higher prostate-cancer specific mortality than men, not of African ancestry. The reasons for the higher burden of disease and disparate outcomes have been attributed, in part, due to social, economic, environmental, and biological […]

(UroToday.com) The 2021 GU ASCO annual meeting included a prostate cancer session ‘Best of the Journals’ with Dr. Hala Borno providing the medical oncology perspective. Dr. Borno provided the following diagram for which papers she was going to discuss based on prostate cancer disease state:

(UroToday.com) The 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium included a presentation by Dr. Ashley Ross discussing the use of genomics to guide treatment decisions in post-prostatectomy patients. Dr. Ross notes that a recent systematic review assessed the clinical utility of the Decipher® genomic classifier recently published in European Urology.1 This genomic […]